Loading
CRB-701 is an experimental antibody-drug conjugate from Corbus Pharmaceuticals in phase 2 trials, aimed at Nectin-4.
CRB-701 is an antibody-drug conjugate developed by Corbus Pharmaceuticals. Its target is Nectin-4 (the sponsor names Nectin-4). ClinicalTrials.gov describes the intervention as: Nectin-4 targeted Antibody Drug Conjugate (ADC). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06265727, plans to enrol 348 participants with primary completion expected 2027-01-16. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Antibody-drug conjugate directed at Nectin-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Nectin-4.
1.CRB-701's antibody arm binds Nectin-4 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CRB-701" OR ABSTRACT:"CRB-701") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRB-701, not a curated reading list.
Shares Corbus Pharmaceuticals and the tag pipeline.
Shares Nectin-4 and the tag pipeline.